Multimorbidity and Sarcopenia Feasibility Study in Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-12

Study Completion Date

2025-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this research study is to look at the body composition (such as muscle and fat) in people with chronic kidney disease (CKD) and comparing it with body composition is people without CKD. The investigators currently understand loss of muscle function and mass (sarcopenia) affect the general health of people as they age, but this process seems to be more common, accelerated, and occurs earlier in people with CKD. There is limited evidence in this area, and we believe that if we understand when and how sarcopenia affects people with CKD, investigators can guide future trials and treatments to help treat sarcopenia, and in turn improve quality of life and health outcomes in people with CKD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease

NCT02405650

Renal Insufficiency, Chronic Obesity

COMPLETED

Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Population of Adult Obese Patients

NCT03394469

Obesity

UNKNOWN NA

The Impact of Misclassification of Obesity by Body Mass Index on Mortality in Patients With Chronic Kidney Disease

NCT03285074

Chronic Kidney Diseases Obesity

COMPLETED

A Prospective Cohort Study of Aged People for Chronic Diseases

NCT02640872

Aging Sarcopenia

COMPLETED

Impact of Physiological, Lifestyle and Genetic Factors on Body Composition

NCT02658539

Body Composition, Beneficial

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the investigators will follow up people with CKD in two visits a year apart. In both visits, the investigators will measure the participants body composition and estimated kidney function using 2 different testing methods - Cystatin C eGFR and Creatinine eGFR. Using both the results in a formula, the creatinine muscle index can be calculated. If this index correlated with sarcopenia, it will be helpful tool in the care of people with CKD as will be a easy to use screening tool for sarcopenia in this population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers

Normal renal function with no kidney disease. Participants with other comorbidities can be included as long as not listed on the exclusion criteria. They will have body composition measured, and eGFR measured.

Cystatin C eGFR

Intervention Type DIAGNOSTIC_TEST

Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Bioimpedance Analysis (Body composition analysis)

Intervention Type OTHER

Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Chronic Kidney Disease Stage 3

People with CKD Stage 3 (eGFR 30-59). They will have body composition measured, and eGFR measured.

Cystatin C eGFR

Intervention Type DIAGNOSTIC_TEST

Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Bioimpedance Analysis (Body composition analysis)

Intervention Type OTHER

Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Chronic Kidney Disease Stage 4

People with CKD 4 (eGFR 15-29). They will have body composition measured, and eGFR measured.

Cystatin C eGFR

Intervention Type DIAGNOSTIC_TEST

Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Bioimpedance Analysis (Body composition analysis)

Intervention Type OTHER

Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Chronic Kidney Disease Stage 5

People with CKD 5 (eGFR \<15), but not on dialysis. They will have body composition measured, and eGFR measured.

Cystatin C eGFR

Intervention Type DIAGNOSTIC_TEST

Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Bioimpedance Analysis (Body composition analysis)

Intervention Type OTHER

Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cystatin C eGFR

Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Intervention Type DIAGNOSTIC_TEST

Bioimpedance Analysis (Body composition analysis)

Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects capable of giving informed consent

≥18 years of age Chronic kidney disease stages 3-5 looked after in secondary care nephrology Healthy volunteers with normal kidney function (Control)

Exclusion Criteria

* Pregnancy
* Subjects with known neuromuscular diseases, e.g. myopathy, muscular dystrophy, muscular atrophy
* Renal transplant recipients
* Patients with pacemakers

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes